Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (2016 - 2026)

Heron Therapeutics filings provide 16 years of Shares Outstanding readings, the most recent being $70000.0 for Q1 2026.

  • On a quarterly basis, Shares Outstanding fell 99.95% to $70000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $70000.0, a 99.95% decrease, with the full-year FY2025 number at $188.3 million, up 23.79% from a year prior.
  • Shares Outstanding hit $188.6 million in Q1 2026 for Heron Therapeutics, up from $70000.0 in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $188.6 million in Q1 2026 to a low of $70000.0 in Q4 2025.
  • Median Shares Outstanding over the past 5 years was $150.3 million (2023), compared with a mean of $132.7 million.
  • Biggest five-year swings in Shares Outstanding: increased 26.36% in 2024 and later crashed 99.95% in 2026.
  • Heron Therapeutics' Shares Outstanding stood at $119.2 million in 2022, then rose by 26.13% to $150.3 million in 2023, then increased by 1.23% to $152.1 million in 2024, then tumbled by 99.95% to $70000.0 in 2025, then changed by 0.0% to $70000.0 in 2026.
  • The last three reported values for Shares Outstanding were $70000.0 (Q1 2026), $70000.0 (Q4 2025), and $183.3 million (Q3 2025) per Business Quant data.